Forbius announces first patient dosed in phase 2a EGFR-overexpressing TNBC trial of AVID100

Image: Forbius has announced that first patient dosed has been dosed in phase 2a triple negative breast cancer clinical trial with AVID100. Photo: courtesy of renjith krishnan / FreeDigitalPhotos.net.